<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880266</url>
  </required_header>
  <id_info>
    <org_study_id>DRM04-HH10</org_study_id>
    <nct_id>NCT03880266</nct_id>
  </id_info>
  <brief_title>A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermira, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of glycopyrronium cloth,
      2.4% when used to treat palmar hyperhidrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Actual">May 24, 2019</completion_date>
  <primary_completion_date type="Actual">May 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline to Week 2 in the hand sweating severity score.</measure>
    <time_frame>From Baseline to Week 2</time_frame>
    <description>The hand sweat severity item is a patient reported outcome, designed to measure the severity of palmar hyperhidrosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have a ≥2 grade improvement in HDSS from baseline at Week 2.</measure>
    <time_frame>From Baseline to Week 2</time_frame>
    <description>Hyperhidrosis Disease Severity Scale (HDSS) is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.
1 (Best), 2, 3, 4 (Worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change from baseline in gravimetrically-measured sweat production at Week 2.</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in gravimetrically-measured sweat production at Week 2.</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have at least a 50% reduction in gravimetrically-measured sweat production from baseline at Week 2.</measure>
    <time_frame>From Baseline to Week 2</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Palmar Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium cloth, 2.4% or vehicle cloth applied to the hands once daily for 14 days (Treatment 4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium cloth, 2.4%</intervention_name>
    <description>Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Pre-saturated 100% polypropylene, nonwoven, fabric cloth</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent and assent (for subjects under legal adult age).

          2. Age ≥9 years.

          3. Primary palmar hyperhidrosis for at least 6 months duration.

          4. Average sweat severity score of ≥4 at Baseline.

          5. HDSS of 3 or 4 at Baseline.

          6. Willing to comply with the protocol. Subjects under legal adult age will be assessed
             by the investigator as to their ability to comply with the protocol.

          7. Male or non-pregnant (negative urine pregnancy test in female subjects of
             child-bearing potential), non-lactating females.

        Exclusion Criteria:

          1. Subjects who have taken or are currently taking Qbrexza (glycopyrronium) cloth, 2.4%.

          2. Prior surgical procedure for hyperhidrosis.

          3. Iontophoresis for the palms within 4 weeks of Baseline.

          4. Treatment with botulinum toxin (e.g., Botox®) for palmar hyperhidrosis within 1 year
             of Baseline.

          5. Open wounds or inflammatory lesions on the hands or, any condition that may alter the
             barrier function of the skin on the hands.

          6. Secondary palmar hyperhidrosis or presence of a condition that may cause secondary
             hyperhidrosis (e.g., lymphoma, malaria, severe anxiety not controlled by medication,
             carcinoid syndrome, substance abuse, hyperthyroidism).

          7. Known history of Sjögren's syndrome or Sicca syndrome.

          8. History of glaucoma, inflammatory bowel disease, toxic megacolon, active febrile
             illness, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe
             ulcerative colitis, toxic megacolon complicating ulcerative colitis or myasthenia
             gravis.

          9. Men with a history of urinary retention requiring catheterization due to prostatic
             hypertrophy or severe obstructive symptoms of prostatic hypertrophy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Doherty</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Dermatology/ ACRC Trials</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

